SCHEMBL2365692

SCHEMBL2365692

COC(=O)c1cccc(Oc2ncc(Cl)cc2Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
LMNA P02545 1/20 0.54
CYP2C9 P11712 1/20 0.54
TSHR P16473 1/20 0.54
APEX1 P27695 1/20 0.54
PPARG P37231 1/20 0.52
NR1H2 P55055 1/20 0.52
NR1H3 Q13133 1/20 0.52
MAPK1 P28482 1/20 0.51
CCR2 P41597 1/20 0.50
MAPT P10636 1/20 0.50
IP6K1 Q92551 2/20 0.49
IP6K3 Q96PC2 1/20 0.49
IP6K2 Q9UHH9 1/20 0.49
LIPE Q05469 3/20 0.49
PTGER4 P35408 2/20 0.48
MET P08581 1/20 0.48
ALK Q9UM73 1/20 0.48
BCHE P06276 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4911339 0.88 L3MBTL1 (0.54) L3MBTL1PPARGNR1H2NR1H3CCR2
SCHEMBL13366027 0.86 NR1H2 (0.53) SMN1; SMN2LMNACYP2C9TSHRAPEX1
SCHEMBL2365611 0.85 PPARG (0.63) SMN1; SMN2LMNACYP2C9TSHRAPEX1
SCHEMBL10515255 0.84 RAB9A (0.65) L3MBTL1SMN1; SMN2LMNAMAPTLIPE
SCHEMBL4907248 0.84 L3MBTL1 (0.51) L3MBTL1LMNANR1H2NR1H3MAPK1
SCHEMBL3507466 0.83 MAPT (0.53) L3MBTL1SMN1; SMN2LMNANR1H2NR1H3
SCHEMBL503071 0.81 PPARG (0.84) PPARG
SCHEMBL2365700 0.81 L3MBTL1 (0.64) L3MBTL1LMNAPPARGNR1H2NR1H3
SCHEMBL4907678 0.79 CCR2 (0.82) CYP2C9CCR2
SCHEMBL22469704 0.77 MRGPRX4 (0.72) L3MBTL1SMN1; SMN2LMNAMAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927549-B2 Adamantyl benzamide derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2015-01-06 US disclosed
US-20110224244-A1 Adamantyl Benzamide Derivatives HIGH POINT PHARMACEUTICALS, LLC (US) 2011-09-15 US disclosed
EP-2362730-A1 ADAMANTYL BENZAMIDE COMPOUNDS High Point Pharmaceuticals, LLC (US) 2011-09-07 EP disclosed
WO-2010059618-A1 ADAMANTYL BENZAMIDE COMPOUNDS HIGH POINT PHARMACEUTICALS, LLC (US) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224244-A1 Adamantyl Benzamide Derivatives HSD11B1, HSD17B11, HSD3B1 L3MBTL1 4221/4885SMN1; SMN2 3441/4885LMNA 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.